Phase 1 Study of ART5803 in Healthy Participants

Key facts

Sponsor

Arialys Therapeutics

Principal Investigator

Sankalp Gokhale, MD, MBA

Arialys Therapeutics

Intervention

ART5803(drug)

Enrollment

64 enrolled

Eligibility

18-65 years · All sexes

Timeline

2024 – 2026

Study locations (1)

• Nucleus Network Pty Ltd, Melbourne, Victoria, Australia

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Autoimmune encephalitis

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT07158229
  Long-term Impact of NMDAR Encephalitis, Level 3
  Hospices Civils de Lyon
• RECRUITINGNCT07477015
  Study of Pathogenic Mechanisms and Identification of Novel Autoantibodies in Autoimmune Encephalitis
  Fondazione Policlinico Universitario Agostino Gemelli IRCCS
• RECRUITINGPHASE3NCT06867991
  Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis
  The First People's Hospital of Changzhou
• RECRUITINGNANCT06584045
  Efficacy and Safety of Calculus Bovis Sativus (CBS) for Adult Encephalitis (CBSinEncephalitis)
  Tongji Hospital
• RECRUITINGNCT07133113
  Medium-term Effects of Treatments in Autoimmune Encephalitis
  Hospices Civils de Lyon
• RECRUITINGNCT06019975
  FDG-PET in the Diagnosis of Autoimmune Encephalitis
  University of Milano Bicocca
• RECRUITINGPHASE3NCT05503264
  A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
  Hoffmann-La Roche
• ACTIVE NOT RECRUITINGNCT07145502
  Monitoring of Outcomes of Cellular and Exosome-based Therapies in Autoinflammatory and Post-infectious Neuroinflammatory Syndromes
  Biocells Medical

See all trials for Autoimmune encephalitis →